Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Subjects must be on a stable dose of guideline-directed medications for Heart Failure (HF).

• Patients will have an established diagnosis of HF before the screening visit, documented by an acceptable imaging modality in the last 6 months.

• Age = 18-80 y

• Body Mass Index (BMI) =23-38 kg/m2

• Glycated hemoglobin (HbA1c) = 6.0-10.0%

• Blood Pressure (BP) \< 145/85 mmHg

• Estimated Glomerular Filtration Rate (eGFR) \> 30 ml/min•1.73 m2

• For women of child-bearing age (WOCBA) willingness to use contraception, if applicable.

Locations
United States
Texas
University of Texas Health Science Center at San Antonio
RECRUITING
San Antonio
Contact Information
Primary
Carolina Solis-Herrera, MD
solisherrera@uthscsa.edu
210-567-4900
Time Frame
Start Date: 2024-01-16
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 10
Treatments
Experimental: Ketone Ester administration
1. Monitored administration of oral Ketone monoester at 400mg/kg dosed twice on visit 2 (cardiac MRI day)~2. Self administered oral β-hydroxybutyrate (BOHB) at 400mg/kg/day for a period of 6 days
Related Therapeutic Areas
Sponsors
Collaborators: National Center for Advancing Translational Sciences (NCATS)
Leads: The University of Texas Health Science Center at San Antonio

This content was sourced from clinicaltrials.gov